The record deal will allow Dassault to offer drugmakers a complete set of services and ride a shift toward personalized medicine, in which research and tools are tailored to individual patient profiles, generating the need to analyze vast amounts of data. Health is becoming a crucial market for Dassault, which also creates 3D design software, said Pascal Daloz, the company’s chief financial officer.
Comments